Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib

Br J Dermatol. 2022 Sep;187(3):432-435. doi: 10.1111/bjd.21252. Epub 2022 May 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Azetidines
  • Dermatomyositis* / complications
  • Dermatomyositis* / drug therapy
  • Humans
  • Inflammation
  • Janus Kinase 1
  • Janus Kinase 2
  • Janus Kinase Inhibitors* / therapeutic use
  • Panniculitis* / drug therapy
  • Panniculitis* / etiology
  • Purines
  • Pyrazoles
  • Sulfonamides

Substances

  • Azetidines
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides
  • Janus Kinase 1
  • Janus Kinase 2
  • baricitinib